Sam Brusco, Associate Editor06.24.24
Tandem Diabetes Care shared real-world insights from a Tandem Mobi with Control-IQ user survey at the 84th Scientific Sessions of the American Diabetes Association (ADA).
The survey found 86% of participants were satisfied or very satisfied with Mobi, regardless of prior therapy. They also agreed that Mobi improved their quality of life.
Tandem Mobi was released in the U.S. in February 2024. According to the company, it’s the world’s smallest, durable automated insulin delivery (AID) system. Mobi’s integrated with Dexcom G7 and G6 continuous glucose monitoring (CGM) systems was also announced last month.
The six-week, limited launch survey targeted early users who were previously using multiple daily injections (MDI), other insulin pumps, or were previous Tandem pump users.
84% of prior MDI users said Mobi reduced the burden of managing diabetes. 82% said it was easy to use, and 77% said Mobi helped them feel they have more freedom in their lives.
78% of prior pump users said Mobi reduced their management burden. 88% said it was easy to use, and 80% said it helped them feel they had more freedom in their lives.
An independent study also shared at ADA showed time in range improved without an increase in time spent below range.
“These real-world user insights provide evidence that we are furthering our mission to improve the lives of people with diabetes by demonstrating that Tandem Mobi not only meets, but exceeds user expectations,” said Jordan Pinsker, MD, chief medical officer at Tandem Diabetes Care. “We are proud to share these results at ADA and will continue to innovate to provide the diabetes community with choice and improved quality of life.”
The survey found 86% of participants were satisfied or very satisfied with Mobi, regardless of prior therapy. They also agreed that Mobi improved their quality of life.
Tandem Mobi was released in the U.S. in February 2024. According to the company, it’s the world’s smallest, durable automated insulin delivery (AID) system. Mobi’s integrated with Dexcom G7 and G6 continuous glucose monitoring (CGM) systems was also announced last month.
The six-week, limited launch survey targeted early users who were previously using multiple daily injections (MDI), other insulin pumps, or were previous Tandem pump users.
84% of prior MDI users said Mobi reduced the burden of managing diabetes. 82% said it was easy to use, and 77% said Mobi helped them feel they have more freedom in their lives.
78% of prior pump users said Mobi reduced their management burden. 88% said it was easy to use, and 80% said it helped them feel they had more freedom in their lives.
An independent study also shared at ADA showed time in range improved without an increase in time spent below range.
“These real-world user insights provide evidence that we are furthering our mission to improve the lives of people with diabetes by demonstrating that Tandem Mobi not only meets, but exceeds user expectations,” said Jordan Pinsker, MD, chief medical officer at Tandem Diabetes Care. “We are proud to share these results at ADA and will continue to innovate to provide the diabetes community with choice and improved quality of life.”